金吾财讯 | 浦银国际发研指,近期康方生物(09926)公布依沃西HARMONi-2 OS数据、宣布依沃西1L PD-L1+ NSCLC适应症中国获批、宣布HARMONi-6试验达到PFS主要终点,为依沃西未来在国际3期试验的成功提升了信心及可预见性。该行指出,2025年后续依沃西催化剂包括:(1)合作伙伴SUMMIT主导的依沃西2L EGFRm NSCLC国际三期HARMONi中期分析顶线数据...
Source Link金吾财讯 | 浦银国际发研指,近期康方生物(09926)公布依沃西HARMONi-2 OS数据、宣布依沃西1L PD-L1+ NSCLC适应症中国获批、宣布HARMONi-6试验达到PFS主要终点,为依沃西未来在国际3期试验的成功提升了信心及可预见性。该行指出,2025年后续依沃西催化剂包括:(1)合作伙伴SUMMIT主导的依沃西2L EGFRm NSCLC国际三期HARMONi中期分析顶线数据...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.